Investing.com -- Merck (NYSE: MRK) fourth-quarter results are expected to frame how the company plans to manage looming Keytruda declines ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE